Andy Chen
Stock Analyst at Wolfe Research
(3.26)
# 1,039
Out of 5,154 analysts
40
Total ratings
53.85%
Success rate
15.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Peer Perform | n/a | $73.05 | - | 1 | Jan 7, 2026 | |
| IMVT Immunovant | Upgrades: Outperform | $50 | $26.66 | +87.55% | 3 | Jan 6, 2026 | |
| KYMR Kymera Therapeutics | Downgrades: Peer Perform | n/a | $83.49 | - | 3 | Jan 6, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $548 | $456.69 | +19.99% | 2 | Jan 6, 2026 | |
| ARGX argenx SE | Downgrades: Peer Perform | n/a | $717.79 | - | 3 | Nov 24, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Peer Perform | n/a | $13.44 | - | 3 | Nov 12, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Peer Perform | n/a | $20.07 | - | 1 | Nov 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $320.66 | - | 3 | Aug 4, 2025 | |
| VERA Vera Therapeutics | Downgrades: Peer Perform | n/a | $39.07 | - | 2 | Aug 4, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $65.36 | -25.03% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $16.71 | - | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $61 | $18.15 | +236.09% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $55.41 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $38.23 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $32.97 | -39.34% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $25.28 | -24.84% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $95.94 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $29.43 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $432.83 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $28.34 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $74.04 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $56.50 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $28.78 | -40.93% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $140.13 | -70.03% | 1 | Feb 15, 2024 |
Apogee Therapeutics
Jan 7, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $73.05
Upside: -
Immunovant
Jan 6, 2026
Upgrades: Outperform
Price Target: $50
Current: $26.66
Upside: +87.55%
Kymera Therapeutics
Jan 6, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $83.49
Upside: -
Vertex Pharmaceuticals
Jan 6, 2026
Upgrades: Outperform
Price Target: $548
Current: $456.69
Upside: +19.99%
argenx SE
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $717.79
Upside: -
Intellia Therapeutics
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $13.44
Upside: -
Apellis Pharmaceuticals
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $20.07
Upside: -
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $320.66
Upside: -
Vera Therapeutics
Aug 4, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $39.07
Upside: -
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $65.36
Upside: -25.03%
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $16.71
Upside: -
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $18.15
Upside: +236.09%
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $55.41
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $38.23
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $32.97
Upside: -39.34%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $25.28
Upside: -24.84%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $95.94
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $29.43
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $432.83
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $28.34
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $74.04
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $56.50
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $28.78
Upside: -40.93%
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $140.13
Upside: -70.03%